CLL Staging: Rai Staging, Binet Staging & CLL-IPI Calculator Explained

CLL staging uses two complementary classification systems — Rai staging (5 stages, 0–IV) and Binet staging (3 groups, A–C) — to assess disease burden in chronic lymphocytic leukaemia. The newer CLL International Prognostic Index (CLL-IPI) integrates clinical staging with biological markers including TP53 status, IGHV mutation, β2-microglobulin, and age for more precise risk stratification. This guide explains all three systems, compares their clinical applications, and provides links to online calculators for point-of-care use.

Rai Staging System for CLL

The Rai staging system was developed in 1975 by Kanti Rai and colleagues and remains the most widely used CLL classification in the United States. It classifies patients into five stages based on progressive accumulation of disease findings.

The Five Rai Stages

| Stage | Findings | Risk Group | Median Survival | |-------|----------|------------|-----------------| | Stage 0 | Lymphocytosis only (>5×10⁹/L) | Low | >10 years | | Stage I | Lymphocytosis + lymphadenopathy | Intermediate | ~7-9 years | | Stage II | Lymphocytosis + hepatomegaly and/or splenomegaly (± lymphadenopathy) | Intermediate | ~7-9 years | | Stage III | Lymphocytosis + anaemia (Hb <11 g/dL) | High | ~1.5-5 years | | Stage IV | Lymphocytosis + thrombocytopenia (platelets <100×10⁹/L) | High | ~1.5-5 years |

Modified Rai Classification

In practice, the five stages are often consolidated into three risk groups — the Modified Rai classification — which simplifies clinical decision-making:

• Low risk (Stage 0): Lymphocytosis alone. These patients typically have an indolent course and may never require treatment.
• Intermediate risk (Stages I–II): Lymphadenopathy or organomegaly present. Most patients are monitored with a watch-and-wait approach until symptomatic progression.
• High risk (Stages III–IV): Cytopenias present due to bone marrow failure. Treatment is generally indicated.

Binet Staging System for CLL

The Binet staging system was developed in 1981 by Jacques-Louis Binet and is the preferred classification in Europe. It assigns patients to one of three groups based on the number of involved lymphoid areas and the presence of cytopenias.

Binet Lymphoid Areas

The Binet system evaluates five lymphoid areas (bilateral sites count as one area each):

1. Cervical lymph nodes (including Waldeyer ring)
2. Axillary lymph nodes
3. Inguinal lymph nodes (including superficial femoral)
4. Spleen (palpable)
5. Liver (palpable)

The Three Binet Stages

| Stage | Criteria | Median Survival | |-------|----------|-----------------| | Stage A | <3 involved lymphoid areas, no anaemia or thrombocytopenia | >10 years | | Stage B | ≥3 involved lymphoid areas, no anaemia or thrombocytopenia | ~7 years | | Stage C | Anaemia (Hb <10 g/dL) and/or thrombocytopenia (platelets <100×10⁹/L), regardless of lymphoid areas | ~2-5 years |

Approximately 60–70% of patients present at Binet stage A, which carries an excellent prognosis. Binet stage C — defined by cytopenias rather than disease bulk — identifies patients with the highest urgency for treatment initiation.

Rai vs Binet: Key Differences

While both systems assess disease burden clinically, they differ in threshold values. Rai defines anaemia as Hb <11 g/dL, while Binet uses Hb <10 g/dL. The Rai system separates lymphadenopathy (stage I) from organomegaly (stage II), whereas Binet combines both into a single lymphoid area count. In practice, the two systems are complementary and often reported together.

CLL-IPI — The Modern Prognostic Index

The CLL International Prognostic Index (CLL-IPI) was published in 2016 by an international working group and represents a significant advance over Rai and Binet staging by incorporating molecular and genetic markers alongside clinical features.

CLL-IPI Scoring

The CLL-IPI assigns points based on five independent prognostic factors:

| Factor | Points | |--------|--------| | TP53 deleted (del(17p)) and/or mutated | 4 | | IGHV unmutated | 2 | | β2-microglobulin >3.5 mg/L | 2 | | Clinical stage: Binet B–C or Rai I–IV | 1 | | Age >65 years | 1 |

Total score range: 0–10

Risk Groups and Outcomes

| Risk Group | Score | 5-Year OS | Recommended Approach | |------------|-------|-----------|---------------------| | Low | 0–1 | 93.2% | Watch and wait | | Intermediate | 2–3 | 79.3% | Watch and wait; treat if symptomatic | | High | 4–6 | 63.6% | Treatment generally indicated | | Very high | 7–10 | 31.3% | Consider clinical trials or aggressive therapy |

The CLL-IPI's key advantage is its ability to identify patients who appear clinically early-stage (Rai 0 / Binet A) but carry high-risk biological features — particularly TP53 aberrations — that predict early progression and treatment resistance.

Which CLL Staging System Should You Use?

Each system has distinct strengths, and modern practice increasingly uses them in combination.

| Feature | Rai | Binet | CLL-IPI | |---------|-----|-------|---------| | Year | 1975 | 1981 | 2016 | | Region | US preferred | Europe preferred | International | | Factors | Clinical only | Clinical only | Clinical + molecular | | Risk groups | 3 (modified) | 3 | 4 | | Molecular markers | No | No | Yes (TP53, IGHV) | | Best for | Initial assessment | Initial assessment | Treatment decisions |

In current practice, the recommended approach is:

1. At diagnosis: Assign both Rai and Binet stages for baseline disease assessment and documentation
2. Before treatment decisions: Calculate the CLL-IPI to incorporate molecular risk factors
3. NCCN and ESMO guidelines both recommend integrating molecular markers (TP53, IGHV, FISH) into the prognostic assessment before initiating therapy

In the UK, NICE guideline NG225 (Chronic lymphocytic leukaemia) recommends Binet staging for initial assessment, with Binet being the preferred system in UK and European practice compared to Rai staging in the US. NICE also recommends integrating IGHV mutation and TP53 status into treatment decisions, aligning with the CLL-IPI approach.

The CLL-IPI does not replace Rai or Binet — it builds upon them. Clinical stage (Rai I–IV or Binet B–C) is itself one of the five CLL-IPI input factors.

Using CLL Staging Calculators at Point of Care

Manual staging is straightforward for Rai and Binet, but the CLL-IPI involves weighted scoring across five variables — making automated calculation valuable for reducing errors and standardising risk assessment.

OncoToolkit provides a validated digital calculator for CLL prognostication:

• CLL-IPI Calculator — Enter TP53 status, IGHV mutation, β2-microglobulin, clinical stage, and age for instant risk group assignment with 5-year overall survival estimates

The calculator uses clearly defined input fields to reduce ambiguity and provides instant results with interpretive guidance from the original 2016 publication. OncoToolkit hosts over 130 oncology calculators spanning staging, prognosis, treatment toxicity, and supportive care.

Frequently Asked Questions

What is the CLL staging system?

CLL is staged using two complementary systems: the Rai staging system (5 stages, 0–IV) primarily used in the United States, and the Binet staging system (3 groups, A–C) preferred in Europe. Both assess disease extent based on lymphocytosis, lymphadenopathy, organomegaly, and cytopenias. The newer CLL-IPI integrates clinical staging with molecular markers (TP53, IGHV) for more precise prognostication.

How many stages of CLL are there?

The Rai system has 5 stages (0 through IV), commonly simplified into 3 risk groups: low (stage 0), intermediate (stages I–II), and high (stages III–IV). The Binet system has 3 stages: A (fewer than 3 involved lymphoid areas, no cytopenias), B (3 or more involved areas), and C (anaemia or thrombocytopenia).

What is the CLL-IPI score?

The CLL-IPI is a modern prognostic index published in 2016 that combines five factors: TP53 status (4 points), IGHV mutation status (2 points), β2-microglobulin >3.5 mg/L (2 points), clinical stage (1 point), and age >65 (1 point). Scores range from 0 to 10 and classify patients into four risk groups — low (0–1), intermediate (2–3), high (4–6), and very high (7–10) — with 5-year overall survival ranging from 93% to 31%.

What is the life expectancy for each CLL stage?

With Rai staging, low-risk (stage 0) patients have median survival exceeding 10 years. Intermediate-risk (stages I–II) patients have median survivals of approximately 7–9 years. High-risk (stages III–IV) patients historically had median survivals of 1.5–5 years, though modern targeted therapies — including BTK inhibitors (ibrutinib, acalabrutinib) and BCL-2 inhibitors (venetoclax) — have substantially improved outcomes across all stages.

Is CLL staging the same as CLL grading?

No. CLL staging (Rai or Binet) classifies disease extent based on clinical findings — lymphadenopathy, organomegaly, and cytopenias. Grading refers to the aggressiveness of malignant cells. CLL is classified as a low-grade (indolent) lymphoproliferative disorder. What varies between patients is the stage (disease burden) and biological risk factors (TP53, IGHV mutation status), not the tumour grade.

This article is intended for healthcare professionals. Prognostic scores provide population-level estimates and should be interpreted within the context of individual patient characteristics, available treatments, and multidisciplinary clinical judgment.